Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Flow Cytometry Characterization of Cerebrospinal Fluid Monocytes in Patients With Postoperative Cognitive Dysfunction: A Pilot Study.

Berger M, Murdoch DM, Staats JS, Chan C, Thomas JP, Garrigues GE, Browndyke JN, Cooter M, Quinones QJ, Mathew JP, Weinhold KJ, Amundsen CL, Bengali S, Brigman BE, Bullock WM, Carter J, Chapman J, Cheong Yee Ching V, Cohen HJ, Colin B, D'Amico TA, Devinney MJ, DeOrio JK, Ellet T, Esclamado RM, Ferrandino MN, Gadsden J, Guercio J, Habib A, Harpole DH, Hartwig MG, Iboaya E, Inman BA, Khan A, Lagoo-Deenadayalan S, Lee PS, Lee WT, Lemm J, Levinson H, Mantyh C, McDonagh DL, Migaly J, Mithani SK, Moretti E, Moul JW, Newman MF, Ni K, Ohlendorf B, Perez A, Peterson AC, Ponussamy V, Preminger GM, Robertson CN, Roman SA, Runyon S, Sandler A, Scheri RP, Smith SK, Talbot L, Thacker JKM, Tong BC, Tu A, Vaslef SN, Waldron N, Wang X, Whitson H, Wickenheisser V, Young C; MADCO-PC Study Team; Markers of Alzheimer’s Disease and neuroCognitive Outcomes after Perioperative Care (MADCO-PC).

Anesth Analg. 2019 Nov;129(5):e150-e154. doi: 10.1213/ANE.0000000000004179.

PMID:
31085945
2.

Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.

Aminsharifi A, Simon R, Polascik TJ, Robertson CN, Sudan DL, Collins BH, Moul JW.

J Urol. 2019 Sep;202(3):469-474. doi: 10.1097/JU.0000000000000207. Epub 2019 Aug 8. Review.

PMID:
30835631
3.

Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.

Tay KJ, Scheltema MJ, Ahmed HU, Barret E, Coleman JA, Dominguez-Escrig J, Ghai S, Huang J, Jones JS, Klotz LH, Robertson CN, Sanchez-Salas R, Scionti S, Sivaraman A, de la Rosette J, Polascik TJ.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):294-299. doi: 10.1038/pcan.2017.8. Epub 2017 Mar 28.

4.

Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients.

Crouzet S, Blana A, Murat FJ, Pasticier G, Brown SCW, Conti GN, Ganzer R, Chapet O, Gelet A, Chaussy CG, Robertson CN, Thuroff S, Ward JF.

BJU Int. 2017 Jun;119(6):896-904. doi: 10.1111/bju.13766. Epub 2017 Mar 10.

5.

High-intensity focused ultrasound for focal therapy: reality or pitfall?

Schulman AA, Tay KJ, Robertson CN, Polascik TJ.

Curr Opin Urol. 2017 Mar;27(2):138-148. doi: 10.1097/MOU.0000000000000372. Review.

PMID:
27997415
6.

Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?

Stewart SB, Moul JW, Polascik TJ, Koontz BF, Robertson CN, Freedland SJ, George DJ, Lee WR, Armstrong AJ, Bañez LL.

Int J Urol. 2014 Dec;21(12):1215-9. doi: 10.1111/iju.12561. Epub 2014 Jul 14.

7.

Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial.

Habib AS, Moul JW, Polascik TJ, Robertson CN, Roche AM, White WD, Hill SE, Nosnick I, Gan TJ; Duke Perioperative Outcome Study Group.

Curr Med Res Opin. 2014 May;30(5):937-43. doi: 10.1185/03007995.2013.877436. Epub 2014 Jan 24.

PMID:
24351100
8.

Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer.

Koontz BF, Quaranta BP, Pura JA, Lee WR, Vujaskovic Z, Gerber L, Haake M, Anscher MS, Robertson CN, Polascik TJ, Moul JW.

Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):88-93. doi: 10.1016/j.ijrobp.2013.05.014. Epub 2013 Jun 19.

PMID:
23790772
9.

Sexual bother and function after radical prostatectomy: predictors of sexual bother recovery in men despite persistent post-operative sexual dysfunction.

Kimura M, Bañez LL, Polascik TJ, Bernal RM, Gerber L, Robertson CN, Donatucci CF, Moul JW.

Andrology. 2013 Mar;1(2):256-61. doi: 10.1111/j.2047-2927.2012.00036.x. Epub 2012 Nov 29.

10.

Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.

Abern MR, Bassett MR, Tsivian M, Bañez LL, Polascik TJ, Ferrandino MN, Robertson CN, Freedland SJ, Moul JW.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):85-90. doi: 10.1038/pcan.2012.38. Epub 2012 Oct 16.

PMID:
23069729
11.

Testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Apr;10(4):502-35. No abstract available.

PMID:
22491049
12.

Complete high-intensity focused ultrasound in prostate cancer: outcome from the @-Registry.

Blana A, Robertson CN, Brown SC, Chaussy C, Crouzet S, Gelet A, Conti GN, Ganzer R, Pasticier G, Thuroff S, Ward JF.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):256-9.

PMID:
22487909
13.

The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection.

Wattson DA, Chen MH, Moran BJ, Dosoretz DE, Braccioforte MH, Salenius SA, D'Amico AV.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e773-9. doi: 10.1016/j.ijrobp.2011.11.023. Epub 2012 Jan 31. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):730. Moul, Judd W [removed]; Robertson, Cary N [removed]; Polascik, Thomas J [removed].

PMID:
22300573
14.

Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.

Stewart SB, Bañez LL, Robertson CN, Freedland SJ, Polascik TJ, Xie D, Koontz BF, Vujaskovic Z, Lee WR, Armstrong AJ, Febbo PG, George DJ, Moul JW.

J Urol. 2012 Jan;187(1):103-8. doi: 10.1016/j.juro.2011.09.040. Epub 2011 Nov 16.

PMID:
22088334
15.

Kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Sep 1;9(9):960-77. No abstract available. Erratum in: J Natl Compr Canc Netw. 2011 Nov 1;9(11):xlv.

PMID:
21917622
16.

Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy.

Kimura M, Bañez LL, Schroeck FR, Gerber L, Qi J, Satoh T, Baba S, Robertson CN, Walther PJ, Donatucci CF, Moul JW, Polascik TJ.

J Sex Med. 2011 Oct;8(10):2935-43. doi: 10.1111/j.1743-6109.2011.02387.x. Epub 2011 Jul 19.

PMID:
21771284
17.

Salvage radiation in men after prostate-specific antigen failure and the risk of death.

Cotter SE, Chen MH, Moul JW, Lee WR, Koontz BF, Anscher MS, Robertson CN, Walther PJ, Polascik TJ, D'Amico AV.

Cancer. 2011 Sep 1;117(17):3925-32. doi: 10.1002/cncr.25993. Epub 2011 Mar 22.

18.

Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.

Ganzer R, Robertson CN, Ward JF, Brown SC, Conti GN, Murat FJ, Pasticier G, Rebillard X, Thuroff S, Wieland WF, Blana A.

BJU Int. 2011 Oct;108(8 Pt 2):E196-201. doi: 10.1111/j.1464-410X.2011.10091.x. Epub 2011 Feb 18.

19.

Clinical predictors of renal mass pathological features.

Tsivian M, Mouraviev V, Albala DM, Caso JR, Robertson CN, Madden JF, Polascik TJ.

BJU Int. 2011 Mar;107(5):735-740. doi: 10.1111/j.1464-410X.2010.09629.x. Epub 2010 Nov 5.

20.

Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Moul JW.

BJU Int. 2011 Jul;108(1):44-8. doi: 10.1111/j.1464-410X.2010.09812.x. Epub 2010 Nov 2.

21.

Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death.

D'Amico AV, Chen MH, Sun L, Lee WR, Mouraviev V, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW.

BJU Int. 2010 Dec;106(11):1618-22. doi: 10.1111/j.1464-410X.2010.09447.x.

22.

Predicting non-organ-confined prostate cancer in men diagnosed after 2000.

Caire AA, Sun L, Lack BD, Lum K, Tang P, Stackhouse DA, Robertson CN, Mouraviev V, Polascik TJ, Albala DM, Moul JW.

Prostate Cancer Prostatic Dis. 2010 Sep;13(3):248-51. doi: 10.1038/pcan.2010.15. Epub 2010 Jun 1.

PMID:
20514082
23.

Predicting occult multifocality of renal cell carcinoma.

Tsivian M, Moreira DM, Caso JR, Mouraviev V, Madden JF, Bratslavsky G, Robertson CN, Albala DM, Polascik TJ.

Eur Urol. 2010 Jul;58(1):118-26. doi: 10.1016/j.eururo.2010.03.011. Epub 2010 Mar 17.

PMID:
20346577
24.

Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death.

Choueiri TK, Chen MH, D'Amico AV, Sun L, Nguyen PL, Hayes JH, Robertson CN, Walther PJ, Polascik TJ, Albala DM, Moul JW.

Cancer. 2010 Apr 15;116(8):1887-92. doi: 10.1002/cncr.25013.

25.

Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate.

Uhlman MA, Sun L, Stackhouse DA, Polascik TJ, Mouraviev V, Robertson CN, Albala DM, Moul JW.

J Urol. 2010 Mar;183(3):997-1001. doi: 10.1016/j.juro.2009.11.046. Epub 2010 Jan 20.

PMID:
20089281
26.

Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW.

J Urol. 2010 Mar;183(3):946-50. doi: 10.1016/j.juro.2009.11.021. Epub 2010 Jan 18.

PMID:
20083275
27.

Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.

Tang P, Sun L, Uhlman MA, Robertson CN, Polascik TJ, Albala DM, Donatucci CF, Moul JW.

Urology. 2010 Nov;76(5):1058-62. doi: 10.1016/j.urology.2009.09.049. Epub 2009 Dec 29.

PMID:
20035982
28.

Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?

Uhlman MA, Sun L, Stackhouse DA, Caire AA, Polascik TJ, Robertson CN, Madden J, Vollmer R, Albala DM, Moul JW.

Urology. 2010 Feb;75(2):460-6. doi: 10.1016/j.urology.2009.06.059. Epub 2009 Oct 12.

29.

Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75.

Caire AA, Sun L, Robertson CN, Polascik TJ, Maloney KE, George DJ, Price MM, Stackhouse DA, Lack BD, Albala DM, Moul JW.

Urology. 2010 May;75(5):1122-7. doi: 10.1016/j.urology.2009.06.091. Epub 2009 Oct 7.

PMID:
19815259
30.

Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.

Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW.

J Urol. 2009 Nov;182(5):2242-8. doi: 10.1016/j.juro.2009.07.034. Epub 2009 Sep 16.

PMID:
19758616
31.

A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.

D'Alonzo RC, Gan TJ, Moul JW, Albala DM, Polascik TJ, Robertson CN, Sun L, Dahm P, Habib AS.

J Clin Anesth. 2009 Aug;21(5):322-8. doi: 10.1016/j.jclinane.2008.09.005. Epub 2009 Aug 22.

PMID:
19700296
32.

Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy.

Xu DD, Sun SD, Wang F, Sun L, Stackhouse D, Polascik T, Albala DM, Moul JW, Caire A, Robertson CN.

Urology. 2009 Sep;74(3):654-8. doi: 10.1016/j.urology.2008.12.063. Epub 2009 Jul 22.

PMID:
19628263
33.

NCCN clinical practice guidelines in oncology: kidney cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):618-30. No abstract available.

PMID:
19555584
34.

NCCN clinical practice guidelines in oncology: testicular cancer.

Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J.

J Natl Compr Canc Netw. 2009 Jun;7(6):672-93. No abstract available.

PMID:
19555582
35.

Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?

Caire AA, Sun L, Ode O, Stackhouse DA, Maloney K, Donatucci C, Mouraviev V, Polascik TJ, Robertson CN, Albala DM, Moul JW.

Urology. 2009 Sep;74(3):643-7. doi: 10.1016/j.urology.2009.02.049. Epub 2009 Jun 7.

PMID:
19501891
36.

Factors predicting prostatic biopsy Gleason sum under grading.

Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW.

J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.

PMID:
19447436
37.

High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.

Blana A, Brown SC, Chaussy C, Conti GN, Eastham JA, Ganzer R, Murat FJ, Pasticier G, Rebillard X, Rewcastle JC, Robertson CN, Thuroff S, Ward JF.

BJU Int. 2009 Oct;104(8):1058-62. doi: 10.1111/j.1464-410X.2009.08518.x. Epub 2009 Apr 17.

38.

Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.

Demark-Wahnefried W, Polascik TJ, George SL, Switzer BR, Madden JF, Ruffin MT 4th, Snyder DC, Owzar K, Hars V, Albala DM, Walther PJ, Robertson CN, Moul JW, Dunn BK, Brenner D, Minasian L, Stella P, Vollmer RT.

Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3577-87. doi: 10.1158/1055-9965.EPI-08-0008.

39.

Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy.

Schroeck FR, Krupski TL, Sun L, Albala DM, Price MM, Polascik TJ, Robertson CN, Tewari AK, Moul JW.

Eur Urol. 2008 Oct;54(4):785-93. doi: 10.1016/j.eururo.2008.06.063. Epub 2008 Jun 23.

PMID:
18585849
40.

Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.

Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW.

Prostate Cancer Prostatic Dis. 2008;11(4):371-6. doi: 10.1038/pcan.2008.18. Epub 2008 Apr 22.

PMID:
18427570
41.

Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.

Price MM, Hamilton RJ, Robertson CN, Butts MC, Freedland SJ.

Urology. 2008 May;71(5):787-91. doi: 10.1016/j.urology.2007.11.036. Epub 2008 Feb 11.

PMID:
18267334
42.

Rectourethral fistula after combination radiotherapy for prostate cancer.

Marguet C, Raj GV, Brashears JH, Anscher MS, Ludwig K, Mouraviev V, Robertson CN, Polascik TJ.

Urology. 2007 May;69(5):898-901.

PMID:
17482930
43.

The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy.

Tseng TY, Cancel QV, Fesperman SF, Kuebler HR, Sun L, Robertson CN, Polascik TJ, Moul JW, Vieweg J, Albala DM, Dahm P.

J Urol. 2007 Apr;177(4):1318-23.

PMID:
17382723
44.

Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience.

Mouraviev V, Nosnik I, Sun L, Robertson CN, Walther P, Albala D, Moul JW, Polascik TJ.

Urology. 2007 Feb;69(2):311-4.

PMID:
17320670
45.

Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.

Moul JW, Sun L, Hotaling JM, Fitzsimons NJ, Polascik TJ, Robertson CN, Dahm P, Anscher MS, Mouraviev V, Pappas PA, Albala DM.

J Urol. 2007 Feb;177(2):499-503; discussion 503-4.

PMID:
17222618
46.

Kidney cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1072-81. No abstract available.

PMID:
17112454
47.

Testicular cancer. Clinical practice guidelines in oncology.

Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 Nov;4(10):1038-58. No abstract available.

PMID:
17112452
48.

Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate.

Anscher MS, Clough R, Robertson CN, Prosnitz LR, Dahm P, Walther P, Donatucci CF, Albala DM, Febbo P, George DJ, Sun L, Moul JW.

Prostate Cancer Prostatic Dis. 2006;9(3):254-60. Epub 2006 Aug 1.

PMID:
16880828
49.

Complications after percutaneous radiofrequency ablation of renal tumors.

Weizer AZ, Raj GV, O'Connell M, Robertson CN, Nelson RC, Polascik TJ.

Urology. 2005 Dec;66(6):1176-80.

PMID:
16360436
50.

Supplement use among men with prostate cancer.

Wiygul JB, Evans BR, Peterson BL, Polascik TJ, Walther PJ, Robertson CN, Albala DM, Demark-Wahnefried W.

Urology. 2005 Jul;66(1):161-6.

PMID:
15992901

Supplemental Content

Loading ...
Support Center